Skip to main content

Blog

Consensus Statement Featuring Expert Insights from PPMD’s Certified Duchenne Care Centers on Access to Novel Therapies for Duchenne Published

...

Roche Announces Phase II Open-Label SHIELD DMD Study to Assess Effect of Satralizumab on Bone Health in Duchenne

...

Summer Fun: Accessible Activities for All Ages and Interests

...

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002

...

NS Pharma Shares Update on VILTEPSO® (Viltolarsen) Phase 3 Study

...

Dyne Therapeutics Shares New Clinical Data from DELIVER Trial of DYNE-251 in Duchenne Patients

...

Study to Explore Barriers to Diverse Clinical Trial Participation in Duchenne Published

...

PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

...

Congress Passes FAA Reauthorization Featuring Monumental Accessibility Improvements

...

Mapping Out a Path Forward: PPMD Convenes Representatives from 21 Academic Centers and 11 Industry Partners for 2024 Cardiac Care Workshop

...